Karin Hellsvik

Karin Hellsvik joined Foghorn Therapeutics in 2022. She brings 20 years of experience and passion for improving patient care, with deep expertise in communications, advocacy, and thought leadership across complex disease areas, spanning early‑stage development through commercialization.

Before joining Foghorn, Karin led corporate affairs for Biogen’s Alzheimer’s business unit, where she oversaw a global team responsible for communications, patient advocacy, and social and digital engagement. Earlier in her tenure at Biogen, she spent four years at the company’s international headquarters in Switzerland, where she established the Patient Advocacy function and strategy across Europe for Biogen’s core disease areas, including multiple sclerosis and rare diseases such as spinal muscular atrophy and ALS. She also served as Biogen’s Head of Patient Communications for the Nordic region, based in Copenhagen.

Prior to Biogen, Karin spent almost 10 years advising a broad range of clients on pharmaceutical communications and advocacy at leading Nordic healthcare communications agencies. She has an educational background in communications and marketing from Sweden and added to her understanding of global healthcare and disparities at MGH Disparities Leadership Program at Mongan Institute Health Policy Research Center, MGH, Boston.